INC (NASDAQ:INCR) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure
INC (NASDAQ:INCR) Files An 8-K Regulation FD Disclosure
Capital City Bank Group, Inc. posted to its internet website (www.ccbg.com)a second quarter 2020 Investor Presentation.
A copy of the presentation materials is being furnished as Exhibit99.1 to this report, substantially in the form intendedto be used.
Exhibit 99.1 is incorporated by reference under this Item 7.01.
In accordance with general instruction B.2 of Current Report onForm 8-K, this information (including Exhibit 99.1) is furnishedand
shall not be deemed filed for purposes of Section 18 of the Securities ExchangeAct of 1934.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.The exhibits listed in the exhibit index are furnished to Regulation FD as part of this Current
Report on Form 8-K and shall not be deemed filed for purposes ofSection 18 of the Securities and Exchange Act
of 1934.
Item No.Description of Exhibit
99.1 Copyof second quarter 2020 Investor Presentation for CapitalCity Bank Group, Inc.
CAPITAL CITY BANK GROUP INC Exhibit
EX-99.1 2 analystpresentation….
To view the full exhibit click
EX-99.1 2 analystpresentation….
To view the full exhibit click
here
About INC (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.